Razpipadon

Last updated

Razpipadon
Razpipadon.svg
Clinical data
Other namesCVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464
Routes of
administration 		Oral [1]
Drug class Dopamine receptor agonist; Dopamine D1 and D5 receptor agonist
Identifiers
  • 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C19H17F2N3O4
Molar mass 389.359 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C
  • InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26)
  • Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. [1] [2] [3] [4] It is taken orally. [1]

Contents

Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors. [1] [2] [5]

The drug was originated by Pfizer and is under development by Cerevel Therapeutics. [1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy. [1]

See also

References

  1. 1 2 3 4 5 6 "CVL 871 - AdisInsight".
  2. 1 2 Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC   7737210 . PMID   33344888.
  3. ↑ Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL (June 2024). "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. doi:10.1080/14728214.2024.2363215. PMID   38822731.
  4. ↑ Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP (July 2023). "An Update on Apathy in Alzheimer's Disease". Geriatrics. 8 (4): 75. doi: 10.3390/geriatrics8040075 . PMC   10366907 . PMID   37489323.
  5. ↑ "CVL-871 - Cerevel Therapeutics". 2 January 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.